MedDataX Logo

Topical Steroids and Cyclosporin-A for COVID-19 Keratoconjunctivitis

NCT ID: NCT04451239

Last Updated: 2020-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-30

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily .

Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keratonjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-19 keratoconjunctivitis

cases will receive topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Group Type OTHER

topical steroids and cyclosporin-A

Intervention Type DRUG

All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

topical steroids and cyclosporin-A

All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COVID-19 Patients with keratoconjunctivitis

Exclusion Criteria

* associated ocular pathology or disease
* other causes of keratoconjunctivitis for example allergic or herpetic
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, Kuwait

OTHER_GOV

Sponsor Role collaborator

Ameera Gamal Abdelhameed

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ameera Gamal Abdelhameed

Lecturer of Ophthalmology

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mona Nasseif, MD

Role: PRINCIPAL_INVESTIGATOR

Tanta University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Farawanyia hospital

Kuwait City, Farawanyia, Kuwait

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kuwait

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ameera Abdelhameed, MD

Role: CONTACT

Phone: 01120090000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mona Nasseif, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVID-19 keratoconjunctivitis

Identifier Type: -

Identifier Source: org_study_id